Literature DB >> 21357719

Heterologous plasmid DNA prime-recombinant human adenovirus 5 boost vaccination generates a stable pool of protective long-lived CD8(+) T effector memory cells specific for a human parasite, Trypanosoma cruzi.

Paula Ordonhez Rigato1, Bruna C de Alencar, José Ronnie C de Vasconcelos, Mariana R Dominguez, Adriano F Araújo, Alexandre V Machado, Ricardo T Gazzinelli, Oscar Bruna-Romero, Mauricio M Rodrigues.   

Abstract

Recently, we described a heterologous prime-boost strategy using plasmid DNA followed by replication-defective human recombinant adenovirus type 5 as a powerful strategy to elicit long-lived CD8(+) T-cell-mediated protective immunity against experimental systemic infection of mice with a human intracellular protozoan parasite, Trypanosoma cruzi. In the present study, we further characterized the protective long-lived CD8(+) T cells. We compared several functional and phenotypic aspects of specific CD8(+) T cells present 14 or 98 days after the last immunizing dose and found the following: (i) the numbers of specific cells were similar, as determined by multimer staining or by determining the number of gamma interferon (IFN-γ)-secreting cells by enzyme-linked immunospot (ELISPOT) assay; (ii) these cells were equally cytotoxic in vivo; (iii) following in vitro stimulation, a slight decline in the frequency of multifunctional cells (CD107a(+) IFN-γ(+) or CD107a(+) IFN-γ(+) tumor necrosis factor alpha positive [TNF-α(+)]) was paralleled by a significant increase of CD107a singly positive cells after 98 days; (iv) the expression of several surface markers was identical, except for the reexpression of CD127 after 98 days; (v) the use of genetically deficient mice revealed a role for interleukin-12 (IL-12)/IL-23, but not IFN-γ, in the maintenance of these memory cells; and (vi) subsequent immunizations with an unrelated virus or a plasmid vaccine or the depletion of CD4(+) T cells did not significantly erode the number or function of these CD8(+) T cells during the 15-week period. From these results, we concluded that heterologous plasmid DNA prime-adenovirus boost vaccination generated a stable pool of functional protective long-lived CD8(+) T cells with an effector memory phenotype.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21357719      PMCID: PMC3088135          DOI: 10.1128/IAI.01190-10

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  57 in total

1.  Lineage relationship and protective immunity of memory CD8 T cell subsets.

Authors:  E John Wherry; Volker Teichgräber; Todd C Becker; David Masopust; Susan M Kaech; Rustom Antia; Ulrich H von Andrian; Rafi Ahmed
Journal:  Nat Immunol       Date:  2003-02-03       Impact factor: 25.606

Review 2.  Early events governing memory CD8+ T-cell differentiation.

Authors:  Joshua J Obar; Leo Lefrançois
Journal:  Int Immunol       Date:  2010-05-26       Impact factor: 4.823

3.  Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes.

Authors:  Sarah C Gilbert; Jörg Schneider; Carolyn M Hannan; Jiang Ting Hu; Magdalena Plebanski; Robert Sinden; Adrian V S Hill
Journal:  Vaccine       Date:  2002-01-15       Impact factor: 3.641

4.  Attrition of T cell memory: selective loss of LCMV epitope-specific memory CD8 T cells following infections with heterologous viruses.

Authors:  L K Selin; M Y Lin; K A Kraemer; D M Pardoll; J P Schneck; S M Varga; P A Santolucito; A K Pinto; R M Welsh
Journal:  Immunity       Date:  1999-12       Impact factor: 31.745

5.  During Trypanosoma cruzi infection CD1d-restricted NK T cells limit parasitemia and augment the antibody response to a glycophosphoinositol-modified surface protein.

Authors:  Malcolm S Duthie; Monika Wleklinski-Lee; Sherilyn Smith; Toshinori Nakayama; Masaru Taniguchi; Stuart J Kahn
Journal:  Infect Immun       Date:  2002-01       Impact factor: 3.441

6.  Immunization with cDNA expressed by amastigotes of Trypanosoma cruzi elicits protective immune response against experimental infection.

Authors:  Silvia B Boscardin; Sheila S Kinoshita; Adriana E Fujimura; Mauricio M Rodrigues
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

7.  AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein.

Authors:  Robert T Schooley; John Spritzler; Hongying Wang; Michael M Lederman; Diane Havlir; Daniel R Kuritzkes; Richard Pollard; Cathy Battaglia; Michael Robertson; Devan Mehrotra; Danilo Casimiro; Kara Cox; Barbara Schock
Journal:  J Infect Dis       Date:  2010-09-01       Impact factor: 5.226

8.  Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates.

Authors:  Thomas W Geisbert; Michael Bailey; Joan B Geisbert; Clement Asiedu; Mario Roederer; Maria Grazia-Pau; Jerome Custers; Peter Jahrling; Jaap Goudsmit; Richard Koup; Nancy J Sullivan
Journal:  J Virol       Date:  2010-07-21       Impact factor: 5.103

9.  Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene.

Authors:  Danilo R Casimiro; Ling Chen; Tong-Ming Fu; Robert K Evans; Michael J Caulfield; Mary-Ellen Davies; Aimin Tang; Minchun Chen; Lingyi Huang; Virginia Harris; Daniel C Freed; Keith A Wilson; Sheri Dubey; De-Min Zhu; Denise Nawrocki; Henryk Mach; Robert Troutman; Lynne Isopi; Donna Williams; William Hurni; Zheng Xu; Jeffrey G Smith; Su Wang; Xu Liu; Liming Guan; Romnie Long; Wendy Trigona; Gwendolyn J Heidecker; Helen C Perry; Natasha Persaud; Timothy J Toner; Qin Su; Xiaoping Liang; Rima Youil; Michael Chastain; Andrew J Bett; David B Volkin; Emilio A Emini; John W Shiver
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

Review 10.  Diversity in T cell memory: an embarrassment of riches.

Authors:  Stephen C Jameson; David Masopust
Journal:  Immunity       Date:  2009-12-18       Impact factor: 31.745

View more
  29 in total

1.  Tc52 amino-terminal-domain DNA carried by attenuated Salmonella enterica serovar Typhimurium induces protection against a Trypanosoma cruzi lethal challenge.

Authors:  Marina N Matos; Silvia I Cazorla; Augusto E Bivona; Celina Morales; Carlos A Guzmán; Emilio L Malchiodi
Journal:  Infect Immun       Date:  2014-07-28       Impact factor: 3.441

2.  Novel vaccine regimen elicits strong airway immune responses and control of respiratory syncytial virus in nonhuman primates.

Authors:  Thomas Grunwald; Matthias Tenbusch; Reiner Schulte; Katharina Raue; Hans Wolf; Drew Hannaman; Rik L de Swart; Klaus Uberla; Christiane Stahl-Hennig
Journal:  J Virol       Date:  2014-01-22       Impact factor: 5.103

3.  Adenovirus vector-induced CD8⁺ T effector memory cell differentiation and recirculation, but not proliferation, are important for protective immunity against experimental Trypanosoma cruzi Infection.

Authors:  José Ronnie Vasconcelos; Mariana R Dominguez; Ramon L Neves; Jonatan Ersching; Adriano Araújo; Luara I Santos; Fernando S Virgilio; Alexandre V Machado; Oscar Bruna-Romero; Ricardo T Gazzinelli; Mauricio M Rodrigues
Journal:  Hum Gene Ther       Date:  2014-03-31       Impact factor: 5.695

Review 4.  Understanding CD8+ T Cell Immunity to Trypanosoma cruzi and How to Improve It.

Authors:  Eva V Acosta Rodríguez; Cintia L Araujo Furlan; Facundo Fiocca Vernengo; Carolina L Montes; Adriana Gruppi
Journal:  Trends Parasitol       Date:  2019-10-10

Review 5.  Advances and challenges towards a vaccine against Chagas disease.

Authors:  Israel Quijano-Hernandez; Eric Dumonteil
Journal:  Hum Vaccin       Date:  2011-11-01

6.  Challenge of chronically infected mice with homologous trypanosoma cruzi parasites enhances the immune response but does not modify cardiopathy: implications for the design of a therapeutic vaccine.

Authors:  Christian Emerson Rosas-Jorquera; Luiz Roberto Sardinha; Fernando Delgado Pretel; André Luis Bombeiro; Maria Regina D'Império Lima; José Maria Alvarez
Journal:  Clin Vaccine Immunol       Date:  2012-12-19

7.  Attenuated and replication-competent vaccinia virus strains M65 and M101 with distinct biology and immunogenicity as potential vaccine candidates against pathogens.

Authors:  Lucas Sánchez-Sampedro; Carmen Elena Gómez; Ernesto Mejías-Pérez; Eva Pérez-Jiménez; Juan Carlos Oliveros; Mariano Esteban
Journal:  J Virol       Date:  2013-04-17       Impact factor: 5.103

8.  High quality long-term CD4+ and CD8+ effector memory populations stimulated by DNA-LACK/MVA-LACK regimen in Leishmania major BALB/c model of infection.

Authors:  Lucas Sánchez-Sampedro; Carmen Elena Gómez; Ernesto Mejías-Pérez; Carlos Oscar S Sorzano; Mariano Esteban
Journal:  PLoS One       Date:  2012-06-08       Impact factor: 3.240

9.  The Immune Response to Trypanosoma cruzi: Role of Toll-Like Receptors and Perspectives for Vaccine Development.

Authors:  Mauricio M Rodrigues; Ana Carolina Oliveira; Maria Bellio
Journal:  J Parasitol Res       Date:  2012-02-16

10.  Rapamycin Improves the Response of Effector and Memory CD8+ T Cells Induced by Immunization With ASP2 of Trypanosoma cruzi.

Authors:  Barbara Ferri Moraschi; Isaú Henrique Noronha; Camila Pontes Ferreira; Leonardo M Cariste; Caroline B Monteiro; Priscila Denapoli; Talita Vrechi; Gustavo J S Pereira; Ricardo T Gazzinelli; Joseli Lannes-Vieira; Maurício M Rodrigues; Karina R Bortoluci; José Ronnie C Vasconcelos
Journal:  Front Cell Infect Microbiol       Date:  2021-05-25       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.